KCNH2 and myocardial infarction: The question of how the actions of hERG activators will react to concomitant presence of one or more drugs (polypharmacy), a genetic predisposition (polymorphism), underlying cardiac condition such as myocardial infarction or a combination of all these aggravating factors as seen in elderly patients7 still needs to be comprehensively addressed.